KLRK1 and acute lymphoblastic leukemia: Chang Yh et al. showed that NK cells expressing the chimeric receptor with NKG2D specificity showed enhanced cytotoxicity against a wide spectrum of tumor subtypes, with the best responses observed in Acute Lymphoblastic Leukemia (ALL), osteosarcoma, prostate carcinoma, and rhabdomyosarcoma [119].